Home
Name
Medroxyprogesterone
Alternate Names
Medroxyprogesterone
Abbreviations
MPA
Category
Hormones and hormonal mechanisms
Subcategory
Hormone
NSC Number
None
Primary Site
Histology
None
Remarks
Medroxyprogesterone has received FDA approval for treatment of advanced and recurrent endometrial cancers. This drug lessens the tumor burden allowing for surgical treatment. If given prior to surgical treatment, code as neo-adjuvant therapy.
In clinical trials for breast cancer and Renal Cell Carcinoma of the kidney.
In clinical trials for breast cancer and Renal Cell Carcinoma of the kidney.
Coding
This drug should be coded
